Physiologic Plasticity of Intramyocardial Lipid Storage
NCT ID: NCT01921075
Last Updated: 2013-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
9 participants
OBSERVATIONAL
2010-01-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. assess the methodological reproducibility of MRS-measurements of cardiac lipids in humans
2. investigate physiological variations of cardiac lipids by measuring day-to-day changes under identical conditions
3. determining diurnal variations of cardiac lipids in humans
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Obesity is a well known risk factor for the development of glucose intolerance, type 2 diabetes mellitus and, consequently, diabetic complications like cardiovascular disease. Importantly, obesity is not only associated with lipid accumulation in adipose tissue (orthotopic fat deposition), but also in non-adipose tissues (ectopic fat deposition). Clinical studies have repetitively shown that muscular and hepatic lipid accumulation as well as elevated visceral adipose tissue is associated with the development of central and peripheral insulin resistance. In addition, recent data from animal studies show increasing evidence that two other organs, the heart and the pancreas, may also be involved in the pathophysiological processes of reduced insulin sensitivity. While reduced insulin secretion in the course of type 2 diabetes has been well documented, the importance of pancreatic fat deposition as an early step in this process has only recently been suggested based on animal models. Conversely, ischemic heart disease is one of the most dangerous complications of diabetes mellitus, its prevention thereby being a cornerstone of current diabetes management. Recent data suggest that changes in the lipid metabolism of the heart and associated epi- and myocardial lipid deposition may be earliest signs of diabetic cardiopathy.
Magnetic-Resonance-Imaging (MRI) and -Spectroscopy (MRS) are among the most versatile methods for non-invasive studies of human tissue and/or metabolism in vivo and in situ. The excellent soft tissue contrast of MRI has already led to the implementation of this method for the assessment of whole body lipid accumulation, whereas MRS has successfully been applied to study lipid metabolism of skeletal muscle and liver. The extended application of this method towards heart and pancreas will allow a comprehensive investigation of orthotopic and ectopic fat deposition in humans and its association with the development of insulin resistance and diabetes mellitus.
The methodological part of the study will focus on the physiologic plasticity of cardiac lipids in order to assess:
i) methodological reproducibility ii) intra-individual physiological reproducibility by measuring day-to-day variations as well as variations during the day.
Objective
i) Adapting and optimizing the single-voxel MRS sequence that is currently used for muscle and liver, such that respiratory and cardiac double-triggering enables spectroscopy of the cardiac muscle.
ii) Validate the methodology under different standardized physiologic conditions.
Methods
Cardiac lipids are determined during five independent MR-examinations distributed over two days separated by one or two weeks. Both days included a measurement in the morning after an overnight fast (\>8h) and one in the afternoon (8h after breakfast, 3.5h after lunch). To determine methodological reproducibility, the afternoon measurement was repeated on one of the two days (1h break). Preparation of the volunteers included perpetuation of their normal diet, but restricted physical activity for two preceding days. Cardiac lipids were determined by single-voxel MR-Spectroscopy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Volunteers
young (age\<30), healthy, lean (BMI\<25) volunteers
normal dietary behavior
normal dietary behavior during examination days
Magnetic resonance spectroscopy
Non-invasive diagnostic procedure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
normal dietary behavior
normal dietary behavior during examination days
Magnetic resonance spectroscopy
Non-invasive diagnostic procedure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 18-30
* BMI \<25
* healthy
* written informed consent
Exclusion Criteria
18 Years
30 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ith, PhD & MD/PhD
Role: PRINCIPAL_INVESTIGATOR
University Institute of Diagnostic Interventional and Pediatric Radiology of the Inselspital Bern
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Diagnostic Interventional and Pediatric Radiology, University Hospital Bern
Bern, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1587
Identifier Type: OTHER
Identifier Source: secondary_id
124/08
Identifier Type: -
Identifier Source: org_study_id